REGENXBIO Prices $100M Offering at $9.00/Share, a 20% Discount to Market

summarizeSummary

REGENXBIO priced a $100M equity offering at $9.00/share, a 20% discount to market, raising ~$94M to fund operations into Q2 2027. The deep discount and dilution pressure existing shareholders.

check_boxKey Events · Financing and Capital Events · RGNX

• $100M Offering Priced at Deep Discount

  10,003,889 shares at $9.00 and 1,111,111 pre-funded warrants at $8.9999, a 20% discount to the July 16 close of $11.20. Underwriters have a 30-day option for 1,667,250 additional shares.

• Net Proceeds of ~$94M Extend Runway

  After fees, REGENXBIO expects ~$93.7M (or ~$107.8M if the option is exercised). Combined with the $100M AbbVie milestone, cash is sufficient into Q2 2027.

• Immediate Dilution of ~18%

  Pro forma shares outstanding rise to ~61.6M (or ~64.4M with option and warrant exercise), diluting existing holders by roughly 18%. Net tangible book value per share increases to $1.86 from $0.41.

• Going Concern Risk Remains

  The company reiterates substantial doubt about its ability to continue as a going concern. The offering buys time but does not resolve the underlying cash burn.

auto_awesomeAnalysis · RGNX · Life Sciences

REGENXBIO priced a $100 million common stock and pre-funded warrant offering at $9.00 per share, a steep 20% discount to yesterday's close of $11.20. The deal includes 10 million shares and 1.1 million pre-funded warrants, with an underwriter option for 1.67 million more shares. Net proceeds of ~$94 million extend the cash runway into Q2 2027, but the deep discount signals weak demand and dilutes existing holders by roughly 18% (pro forma). This follows a preliminary filing yesterday and comes amid going concern doubts, though recent positive pipeline news (RGX-202 Phase III data, AbbVie milestone) provides a backdrop.